VIRBAC |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 359.5 EUR | +0.70% |
|
-0.14% | 0.00% |
| Apr. 17 | VIRBAC : A healthy start to 2024; outlook re-iterated |  |
| Apr. 17 | Virbac: sales up by almost 10% in Q1 | CF |
Business Summary
- pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips;
- livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc.
Net sales are distributed geographically as follows: France (15.8%), Europe (24.9%), Asia (17.5%), Latin America (16.2%), North America (13.3%), Pacific (9.7%), Africa and Middle East (2.6%).
Number of employees: 5,459
Sales per Business
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Production Animals - Other Ruminants
16.8
%
| 172 | 16.2 % | 204 | 16.8 % | +18.56% |
Pets- Specialties
10.9
%
| 112 | 10.5 % | 133 | 10.9 % | +19.10% |
Pets - Parasiticides
10.1
%
| 108 | 10.2 % | 123 | 10.1 % | +13.38% |
Pets - Others
10.1
%
| 101 | 9.5 % | 122 | 10.1 % | +20.85% |
Pets - Antibiotics/Dermatology
9.1
%
| 101 | 9.5 % | 111 | 9.1 % | +9.61% |
Pets - Specialized Food
8.1
%
| 78 | 7.4 % | 99 | 8.1 % | +25.64% |
Production Animals - Bovine Antibiotics
7.1
%
| 81 | 7.6 % | 86 | 7.1 % | +6.04% |
Pets - Immunology
7.0
%
| 77 | 7.2 % | 85 | 7.0 % | +10.79% |
Production Animals - Bovine Parasiticides
6.2
%
| 58 | 5.4 % | 76 | 6.2 % | +31.77% |
Production Animals - Aquaculture
3.6
%
| 48 | 4.5 % | 44 | 3.6 % | -6.93% |
Production Animals - Other Pig/Poultry
3.0
%
| 33 | 3.1 % | 37 | 3.0 % | +9.28% |
Pets - Equine
2.8
%
| 32 | 3.0 % | 34 | 2.8 % | +6.01% |
Production Animals - Pig/Poultry Antibiotics
2.6
%
| 35 | 3.3 % | 32 | 2.6 % | -7.51% |
Other
2.6
%
| 29 | 2.7 % | 32 | 2.6 % | +10.42% |
Sales per region
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Europe (excluding France)
24.9
%
| 281 | 26.4 % | 303 | 24.9 % | +7.75% |
Asia
17.5
%
| 184 | 17.2 % | 213 | 17.5 % | +16.04% |
Latin America
16.2
%
| 167 | 15.7 % | 197 | 16.2 % | +18.05% |
France
15.8
%
| 185 | 17.4 % | 192 | 15.8 % | +3.85% |
North America
13.3
%
| 124 | 11.7 % | 162 | 13.3 % | +30.38% |
Pacific
9.7
%
| 94 | 8.9 % | 118 | 9.7 % | +24.75% |
Africa & Middle East
2.7
%
| 30 | 2.8 % | 32 | 2.7 % | +9.33% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Sébastien Huron
CEO | Chief Executive Officer | 54 | 05-12-31 |
Habib Ramdani
DFI | Director of Finance/CFO | 48 | 16-01-31 |
Sophie Favini
COO | Chief Operating Officer | - | 23-06-30 |
| Chief Tech/Sci/R&D Officer | - | 94-04-30 | |
Sandrine Brunel
IRO | Public Communications Contact | - | 98-10-31 |
Michel Garaudet
IRC | Investor Relations Contact | 69 | 02-11-30 |
Marc Bistuer
PRN | Corporate Officer/Principal | 63 | 20-12-14 |
| Human Resources Officer | - | 15-04-30 | |
Nathalie Pollet
SAM | Sales & Marketing | - | 92-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 10-12-31 | |
Philippe Capron
BRD | Director/Board Member | 64 | 03-12-31 |
| Chairman | 59 | 97-12-31 | |
| Director/Board Member | 63 | 94-12-31 | |
| Director/Board Member | 53 | 19-06-17 | |
| Director/Board Member | 30 | 17-09-04 | |
Sylvie Gueguen
BRD | Director/Board Member | 59 | 18-10-29 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 8,458,000 | 4,193,415 ( 49.58 %) | 88,281 ( 1.044 %) | 49.58 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
VIRBAC 0.19% | 15,852 | 0.19% | 5,923,576 $ |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Bio Veto Tests SA
 Bio Veto Tests SA Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Bio Veto Tests SA is a French company that develops vaccines against viral and parasitic diseases in companion animals. The private company is based in Sanary sur Mer, France. Bio Veto Tests was acquired by Virbac SA on May 07, 2003. |
Pharmaceuticals: Major
|
Virbac Nutrition SAS
 Virbac Nutrition SAS Food: Specialty/CandyConsumer Non-Durables Part of Virbac SA, Virbac Nutrition SAS is a French company that manufactures and wholesales pet food. The private company is based in Vauvert, France. The company was founded in 1987. Philippe Domptail has been the CEO of the company since 2011. |
Food: Specialty/Candy
|
Virbac (Australia) Pty Ltd.
 Virbac (Australia) Pty Ltd. Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Virbac (Australia) Pty Ltd. is an Australian company that manufactures veterinary pharmaceuticals and vaccines. The private company is based in Milperra, Australia. |
Pharmaceuticals: Major
|
Virbac RSA (Pty) Ltd.
| |
Virbac Animal Health India Pvt Ltd.
| |
Virbac Ltd.
 Virbac Ltd. Medical DistributorsDistribution Services Part of Virbac SA, Virbac Ltd. is a British company that wholesales pharmaceutical products. The private company is based in Bury St. Edmunds, UK. Founded in 1986. |
Medical Distributors
|
Virbac New Zealand Ltd.
 Virbac New Zealand Ltd. Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Virbac New Zealand Ltd. is a New Zealander company that manufactures medicines for animals. The private company is based in Auckland, New Zealand. |
Pharmaceuticals: Major
|
Virbac Mexico SA de CV
 Virbac Mexico SA de CV Pharmaceuticals: MajorHealth Technology Part of Virbac SA, Virbac Mexico SA de CV is a Mexican pharmaceutical company that manufactures pharmaceutical products. The private company is based in Guadalajara, Mexico. |
Pharmaceuticals: Major
|
Virbac Danmark A/S
|
Sector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.70% | 3.18B | |
| -26.26% | 66.5B | |
| -13.22% | 6.37B | |
| +15.88% | 3.43B | |
| +7.09% | 1.49B | |
| -15.13% | 1.37B | |
| -4.59% | 1.23B | |
| -27.91% | 1.21B | |
| -12.02% | 1.15B | |
| -2.68% | 1.02B |
- Stock Market
- Equities
- VIRP Stock
- Company Virbac
